PainReform Ltd. (NASDAQ:PRFX) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 18,700 shares, a drop of 92.1% from the September 15th total of 236,800 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is presently 0.0 days.
PRFX stock opened at $2.63 on Thursday. The firm has a 50 day moving average of $2.81 and a 200 day moving average of $3.03. PainReform has a 52 week low of $2.18 and a 52 week high of $7.84.
A number of hedge funds have recently added to or reduced their stakes in PRFX. Virtu Financial LLC purchased a new position in PainReform during the 2nd quarter worth approximately $33,000. Goldman Sachs Group Inc. purchased a new position in PainReform during the 2nd quarter worth approximately $49,000. Citadel Advisors LLC raised its position in PainReform by 22.0% during the 2nd quarter. Citadel Advisors LLC now owns 33,735 shares of the company’s stock worth $95,000 after buying an additional 6,073 shares during the last quarter. Sabby Management LLC raised its position in PainReform by 5.3% during the 2nd quarter. Sabby Management LLC now owns 347,468 shares of the company’s stock worth $980,000 after buying an additional 17,468 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in PainReform during the 1st quarter worth approximately $3,710,000. Institutional investors own 12.56% of the company’s stock.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Read More: Index Funds
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.